SynthesisInternational journal of molecular sciences2026
Prognostic and Clinicopathological Significance of CD74 Expression in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, and reliable prognostic biomarkers are urgently needed to guide risk stratification and treatment. CD74 has been implicated in tumor progression, invasion, and pro-inflammatory signaling in various cancers. This systematic review and meta-analysis aimed to evaluate the association between CD74 expression and key clinicopathological features and survival outcomes in patients with PDAC. A systematic literature search was conducted in PubMed, Web of Science, and Scopus to identify eligible studies reporting on CD74 expression in PDAC tissues (PROSPERO: CRD420261402709). Studies were selected following the PRISMA 2020 guidelines. The methodological quality of the included studies was assessed using the QUIPS tool. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for the associations between CD74 expression and perineural invasion (PNI), lymphatic invasion, lymph node metastasis (pN), vascular permeation, pTNM stage, and overall survival. Statistical analyses were performed using Review Manager v5.4. DerSimonian-Laird random-effects models were applied as sensitivity analysis for every outcome, with Mantel-Haenszel fixed-effects models as the primary analysis according to the level of heterogeneity, which was quantified using the I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.